Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation.
Twenty patients with Hodgkin's disease which had relapsed at least once after chemotherapy, were treated with melphalan 140-220 mg/m2 i.v. followed by reinfusion of non-cryopreserved autologous bone marrow. Four patients (20%) remain alive and disease-free 28, 45, 52, and 96 months after treatment respectively. There were no treatment-related deaths. This appears to be the only reported series of patients treated with a single agent in this situation. The results are comparable to those achieved by multi-agent regimens with autologous or allogeneic bone marrow transplantation.
Russell
J A
JA
Department of Medicine, Tom Baker Cancer Centre and Foothills Hospital, Calgary, Canada.
Selby
P J
PJ
Ruether
B A
BA
Mbidde
E K
EK
Ashley
S
S
Zulian
G
G
Berry
J
J
Houwen
B
B
Jones
A R
AR
Poon
M C
MC
D000328:Adult; D016026:Bone Marrow Transplantation; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D014182:Transplantation, Autologous
D008558:Melphalan